Sunday 18 October 2026
Export CYTT’s income statement to Excel — free account
Cyteir Therapeutics, Inc.
CYTT Healthcare Biotechnology
Dividend growth for five consecutive years.
3.01
0.00
0.00%
Follow CYTT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 9.72 | 1.13 |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 23.10 | 11.62 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 31 | 40 | 46 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | (2,587.50) | 0.00 | 0.00 | 0.00 | |||||
| EBT | — | — | — | — | — | — | (15) | (21) | (42) | (46) | |||||
| EBT margin, % | — | — | — | — | — | — | (188,050.00) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | 0 | — | (15) | (21) | (42) | (46) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (3.42) | (13.60) | (2.16) | (1.31) | |||||
| Cash flow | — | — | — | — | — | — | (3.99) | (12.11) | (1.85) | (1.21) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.56) | (0.06) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (3.99) | (12.66) | (1.91) | (1.21) | |||||
| Book value | — | — | — | — | — | — | 6.61 | (31.37) | 9.61 | 4.15 | |||||
| Shares, m | — | — | — | — | — | — | 4 | 2 | 19 | 35 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.20 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | 5.87 | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (18) | (19) | (36) | (43) | ||||
| Capex | — | — | — | — | — | — | 0 | (1) | (1) | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (18) | (19) | (37) | (43) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 28 | 9 | 186 | 144 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | 2 | |||||
| Net debt | — | — | — | — | — | — | (29) | (11) | (190) | (147) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 29 | (48) | 187 | 146 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (95.92) | (92.33) | (40.29) | (26.42) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 39.40 | 54.53 | (60.50) | (27.62) | |||||
Negative figures in brackets.
Fiscal years to Dec 2019
Charts ten years each
Cyteir Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SEER Seer, Inc. | $113.0M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| FHTX Foghorn Therapeutics Inc. | $112.2M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| GNLX Genelux Corporation | $112.2M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $112.2M | — (loss-making) | — (loss-making) | +9.72% (above 0%: growing) | n/m | −229.66% (below 0%: shrinking) | 94.90% | (622.89%) | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $110.1M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| VTVT vTv Therapeutics Inc. | $109.1M | — (loss-making) | — (loss-making) | +409,222.22% (above 0%: growing) | n/m | −124.59% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CYTT Cyteir Therapeutics, Inc. | $108.7M | — (loss-making) | — | — | n/m | +63.78% (above 0%: growing) | 0.00% | 0.00% | |
| INO Inovio Pharmaceuticals, Inc. | $107.5M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VANI Vivani Medical, Inc. | $103.7M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $111.1M | — | — | +9.72% | — | −5.39% | 97.45% | (27.39%) |
Cyteir Therapeutics, Inc. (CYTT) key facts
- Cyteir Therapeutics, Inc. (CYTT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of May 31, 2024, CYTT traded at $3.01, a market capitalization of $108.7 million.
- Return on equity was −27.6% and debt-to-equity 0.00.
Cyteir Therapeutics, Inc. (CYTT) Latest News
No news at this impact. Lower the threshold for more.